duration of complete response
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Lihua E Budde, Huilai Zhang, Won-Seog Kim, Dai Maruyama, Eduardo M Rego, Lalita Norasetthada, Huangming Hong, Muhit Ozcan, Young-Woo Jeon, Danielle Leão Cordeiro de Farias, Laura Maria Fogliatto, Astrid Pavlovsky, Hideki Goto, Adam J Olszewski, Nikesh Shah, Bei Hu, Shen Yin, Hao Wu, Iris To, Wahib S Ead, Joan Ashby, Martin Janousek, Song Pham, Jue Wang, Antonia Kwan, Connie L Batlevi, Michael C Wei, Jason Westin
J Clin Oncol 43(36) 3799-3811
PURPOSE: Prognosis for patients with refractory/relapsed large B-cell lymphoma (LBCL) considered ineligible for curative-intent therapy is poor. The combination of mosunetuzumab, a T-cell-engaging bispecific antibody, and polatuzumab vedotin, an antibody-drug conjugate (Mosun-Pola), represents a novel fixed-duration outpatient therapy. METHODS: In the phase III SUNMO trial, patients with refractory/relapsed LBCL who were ineligible for autologous stem-cell transplant were randomly assigned (2:1) to receive Mosun-Pola or rituximab, gemcitabine, and oxaliplatin (R-GemOx). Dual primary end points were centrally assessed overall response rate (ORR) and progression-free survival (PFS). Overall survival was a key secondary end point. RESULTS: A total of 208 patients were randomly assigned to receive Mosun-Pola (n = 138) or R-GemOx (n = 70). At a median follow-up of 23.2 months, the primary analysis of SUNMO demonstrated that the median PFS was significantly longer with Mosun-Pola than with R-GemOx (11.5 months [95% CI, 5.6 to 18] v 3.8 months [95% CI, 2.9 to 4.1]; hazard ratio for progression or death, 0.41 [95% CI, 0.3 to 0.6]; P < .0001). ORR was significantly greater with Mosun-Pola versus R-GemOx (70% v 40%; P < .0001), with complete response rates of 51% and 24%, respectively. In the Mosun-Pola group, the rate of grade ≥2 cytokine release syndrome (CRS) and usage of tocilizumab occurred in <5% of patients and patient-reported outcomes were improved compared with R-GemOx. CONCLUSION: Mosun-Pola demonstrated superior efficacy versus R-GemOx, with significant improvements in both ORR and PFS, and infrequent CRS events with a manageable safety profile.
1 个 Figure · 3 个 KM 面板
FIG 2. Kaplan-Meier estimates of (A) duration of complete response, (B) centrally assessed PFS, and (C) OS in the primary analysis (intent-to-treat population). GemOx, gemcitabine plus oxaliplatin; Mosun, mosunetuzumab; NE, not estimable; OS, overall survival; PFS, progression-free survival; Pola, polatuzumab vedotin; R, rituximab.
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 2. · Panel B
Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 2. · Panel C
Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。